Cancer Association of South Africa (CANSA)

Fact Sheet on Bowen’s Disease

Introduction
Skin cancer develops primarily on areas of sun-exposed skin. These include the scalp, face, lips, ears, neck, chest, arms and hands, and on the legs in women. It can also appear on areas that rarely see the light of day — the palms, beneath the fingernails or toenails, and the genital area, especially in individuals with darker skin tones.

Skin cancer affects people of all skin tones, including those with darker complexions. When melanoma occurs in people with dark skin tones, it is more likely to occur in areas not normally exposed to the sun.

Bowen’s Disease
Bowen’s disease is a very early form of squamous cell skin cancer. It is also called squamous cell carcinoma in situ. Bowen’s disease is often referred to as ‘pre-invasive’. This means that there are cancer cells present but they are only in the outermost layer of skin, the epidermis. Sometimes it can spread along the skin surface.

If left untreated, there is a chance that Bowen’s disease can spread into the deeper layers of the skin. This means it has become an invasive cancer and can then spread into the lymphatic system. It takes a long time for Bowen’s disease to develop into an invasive cancer. The risk, however, of developing into a fully blown skin cancer remains until
Bowen’s disease is treated.

**Wozniak-Rito, A.M. & Rednicka, L. 2018.**

“Bowen’s disease, named after John Templeton Bowen, also known as squamous cell carcinoma in situ is a type of non-melanocytic intraepidermal malignancy. It is estimated that in general population around 3% to 5% of Bowen's disease transform into invasive squamous cell cancer. Dermoscopy aims in the identification of the Bowen's disease. The most typical dermoscopic features of Bowen's disease include glomerular vessels and scaly surface. Although dermoscopy of Bowen's disease has been well established other skin lesions may present similar or identical structures in dermoscopic images leading to differential diagnosis dilemmas. Histopathological confirmation should be obtained prior the treatment of suspected cases of Bowen's disease in order to avoid a misdiagnosis.”

**Incidence of Squamous Cell Carcinoma (SCC) in South Africa**
The National Cancer Registry (2014) does not provide any information regarding the incidence of Bowens/ Disease in South Africa.

**Scalvenzi, M., Villani, A., Mazzella, C., Fabbrocini, G. & Costa, C. 2019.**

“Bowen’s disease (BD), also known as squamous cell carcinoma in situ, is a type of non-melanocytic intraepidermal malignancy characterised by a slowly enlarging erythematous to pink, scaly patch or plaque with irregular and well-demarcated borders. These lesions are usually persistent and progressive; it has been estimated that in general population around 3% to 5% of Bowen's disease transform into invasive squamous cell carcinoma. This report describes our experience with cutaneous BD and assesses the differences found about age, sex and anatomical site. Bowen's disease was seen more frequently in male patients rather than in female patients in contrast to what confirmed in literature - this difference is probably because being head-neck an exposed region, patients are more easily induced to autoexam and to consult the dermatologist.”

**Signs and Symptoms of Bowen’s Disease**
Bowen’s disease can occur anywhere on the body but is usually found on the lower legs. To begin with, it often looks like a red, scaly patch, or sometimes like raised spots or warts. The affected skin may become itchy, sore and may bleed. As Bowen’s disease can look like other skin conditions such as eczema or psoriasis, it is important to get any skin problems checked by a doctor, preferably a dermatologist.

**Diagnosis of Bowen’s Disease**
Diagnosis of Bowen’s Disease is done by means of a shave or punch biopsy for histological diagnosis. Where possible, it is suggested that a hair follicle should be included in the biopsy material.

The following conditions should be considered as possibilities in differential diagnosis:
- Actinic Keratosis
- Basal Cell Carcinoma
- Lichen Simplex Chronicus
- Paget Disease (mammary)
- Psoriasis (plaque)
- Squamous Cell Carcinoma
- Tinea Corporis

Risk Factors of Bowen’s Disease
Risk factors for Bowen’s Disease include:

Sun damage – UV exposure in sunlight (especially with fair skin) is a strong risk factor
Other irradiation damage - radiotherapy, photochemotherapy
Carcinogens - particularly arsenic. Exposure to inorganic arsenic is less common than it used to be in the past.
Viral infection - There is a strong association with human papillomavirus (HPV), HPV-16 particularly in genital and perianal lesions. Some other HPV types have also been implicated.
Immunosuppression - following organ transplants, or Aids. Malignant and premalignant skin tumours are more common in patients who have received organ transplants.
Chronic skin injury or dermatoses - it may arise (rarely) in pre-existing skin lesions such as seborrhoeic keratoses

Staging of Skin Cancer
Doctors use a staging system that is common to all cancers. It is called the TNM system:

- The T indicates the size and depth of the tumour
- The N shows whether the cancer has spread to the lymph nodes
- The M shows whether the cancer has spread to another part of the body (metastasis)

Treatment of Bowen’s Disease
There are a number of treatment options and one’s dermatologist should take into consideration where the patch is on one’s body, as well as its size, thickness and the number of patches one has before deciding on the most appropriate treatment.

He/she will also consider how well the skin is likely to heal afterwards – for example, skin on the lower legs tends to be tight, fragile and slower to heal.

Treatment options may include:

- Cryotherapy – Liquid nitrogen is sprayed onto the affected skin to freeze it. The procedure may be painful and the skin may remain a bit uncomfortable for a few days.
- Application of skin creams – This is applied to the affected skin regularly as prescribed.
- Curettage and cautery – The affected area of skin is scraped away under local anaesthetic.
• Photodynamic therapy – A light-sensitive cream is applied to the affected skin, and a laser is directed onto the skin four to six hours later, to destroy the abnormal cells.


BACKGROUND: Photodynamic treatment with methyl aminolevulinate (MAL-PDT) is considered an effective and highly recommended treatment for Bowen's disease. However, its long-term efficacy remains to be established, as significant differences have been reported in this respect.

OBJECTIVE: The aim of the present study was to describe the results of a retrospective analysis of patients with Bowen's disease treated with MAL-PDT during the period 2006-17 at the Costa del Sol Hospital (Marbella, Spain).

MATERIAL AND METHODS: This study is based on a retrospective descriptive analysis of the clinical records of patients treated with MAL-PDT from June 2006 to September 2017. The analysis was based on calculating the mean and standard deviation values for the quantitative variables, and frequency distributions for the qualitative ones. The survival curves were plotted by the Kaplan-Meier method, and the log-rank test was used to assess differences in survival between groups. A cox regression analysis was performed to clarify the significant prognostic factors.

RESULTS: A total of 537 tumours with histologically confirmed Bowen's disease were treated with MAL-PDT. Recurrence-free survival at one year was 88%, and at 5 years, 71%. Tumour size >300 mm² (≥21 mm in diameter P = 0.019), its location in the upper extremities (P = 0.029) and patient’s age <70 years (P = 0.028) were all associated with an increased risk of recurrence.

LIMITATIONS: Given the retrospective design of our study, the possible existence of information bias cannot be ruled out.

CONCLUSIONS: Although it is an appropriate treatment option for patients with Bowen's disease, MAL-PDT presents a risk of recurrence of almost 30% at 5 years. Larger lesions (>300 mm²; ≥21 mm in diameter) are more likely to recur than smaller ones. Therefore, appropriate selection is needed of the tumour to be treated, and prolonged follow-up should be provided.


“The aim of this review is to provide clinicians with an overview of outcomes in the current literature concerning the use of Photodynamic Therapy to treat Bowen’s Disease, also known as Squamous Cell Carcinoma in situ. The review discusses clinical response, recurrence rates, cosmetic outcomes, and adverse effects. Strong evidence shows that PDT is an effective therapy for SCCis with acceptable clinical response rates and lower recurrence rates in comparison to conventional therapies such as cryotherapy and 5-fluorouracil. Furthermore, PDT is associated with superior cosmetic outcomes and is generally well tolerated by patients, with minimal side effects. PDT is especially useful in patients with multiple lesions and those whom are considered to be non-surgical candidates.”

• Surgery – The abnormal skin is cut out and stitches may be needed afterwards.


“There are only a few anecdotal case reports about Bowen's disease (BD) treated with ingenol mebutate (IM) gel but no clinical study has been published yet. The aim of this study was to evaluate the effectiveness of IM gel in the treatment of BD and to observe the therapeutic efficacy of IM alone or IM with ablative fractional laser pretreatment. Nineteen patients with BD or squamous cell carcinoma in situ confirmed by skin biopsy were enrolled. IM was applied with 0.015% gel on facial lesions for 3 days consecutively and 0.05% gel on other sites for 2 days consecutively, with a 5-mm
application margin around the visible lesion. Nine patients applied IM gel immediately following fractional CO₂ laser treatment. Two patients were lost to follow up and a total of 17 patients were enrolled. Nine patients (9/17, 52.9%) had a clinically complete response at 2 months after treatment. Among the patients treated with the fractional CO₂ laser before applying IM gel, eight (8/9, 88.9%) showed a complete response and one (1/9, 11.1%) showed partial response. Among the patients treated with IM gel alone, only one patient (1/8, 12.5%) showed a complete response, four (4/8, 50%) showed a partial response and three (3/8, 37.5%) did not respond to therapy. IM gel alone seems to have limited value for treatment of BD; however, a combination therapy with the ablative fractional laser can increase its therapeutic effectiveness.

**About Clinical Trials**
Clinical trials are research studies that involve people. They are conducted under controlled conditions. Only about 10% of all drugs started in human clinical trials become an approved drug.

Clinical trials include:
- Trials to test effectiveness of new treatments
- Trials to test new ways of using current treatments
- Tests new interventions that may lower the risk of developing certain types of cancers
- Tests to find new ways of screening for cancer

The **South African National Clinical Trials Register** provides the public with updated information on clinical trials on human participants being conducted in South Africa. The Register provides information on the purpose of the clinical trial; who can participate, where the trial is located, and contact details.

For additional information, please visit: [www.sanctr.gov.za/](http://www.sanctr.gov.za/)

**Medical Disclaimer**
This Fact Sheet is intended to provide general information only and, as such, should not be considered as a substitute for advice, medically or otherwise, covering any specific situation. Users should seek appropriate advice before taking or refraining from taking any action in reliance on any information contained in this Fact Sheet. So far as permissible by law, the Cancer Association of South Africa (Cansa) does not accept any liability to any person (or his/her dependants/estate/heirs) relating to the use of any information contained in this Fact Sheet.

Whilst CANSA has taken every precaution in compiling this Fact Sheet, neither it, nor any contributor(s) to this Fact Sheet can be held responsible for any action (or the lack thereof) taken by any person or organisation wherever they shall be based, as a result, direct or otherwise, of information contained in, or accessed through, this Fact Sheet.
Sources and References Consulted or Utilised


Bowen's Disease
http://wikisickness.com/bowens-disease.html
https://escholarship.org/uc/item/8h88k004

Bowen's Disease 2

Cancer Research UK
http://www.cancerresearchuk.org/about-cancer/type/rare-cancers/rare-cancers-name/what-is-bowens-disease


John T Bowen


MacMillan Cancer Support
http://www.macmillan.org.uk/Cancerinformation/Cancertypes/Skin/Pre-cancerousconditions/Bowensdisease.aspx


NHS.UK
http://www.nhs.uk/conditions/bowens-disease/Pages/Introduction.aspx


Patient.co.uk
http://www.patient.co.uk/doctor/bowens-disease-pro

Researched and Authored by Prof Michael C Herbst
[D Litt et Phil (Health Studies); D N Ed; M Art et Scien; B A Cur; Dip Occupational Health; Dip Genetic Counselling; Diagnostic Radiographer; Dip Audiometry and Noise Measurement; Medical Ethicist]
Approved by Ms Elize Joubert, Chief Executive Officer [BA Social Work (cum laude); MA Social Work]
April 2019


Wikipedia
http://en.wikipedia.org/wiki/Bowen%27s_disease
